Teleflex , Inc. (NYSE: TFX ) Q2 2014 Earnings Call July 30, 2014 8:00 am ET Executives Jake ..... day, ladies and gentlemen, and welcome to the Second Quarter 2014 Teleflex Incorporated Earnings Conference Call. My name is Nina, and I
Teleflex (NYSE: TFX ) Q2 results : Net Revenues: $468.1M (+11.4%), Vascular NA: $64.2M (+13.5%), Anesthesia/Respiratory NA
The FDA grants 510(k) clearance to Teleflex (NYSE: TFX ) subsidiary Hotspur Technologies' Arrow GPSCath Balloon Dilation Catheter designed for use with .014" guide wires and in 150
The FDA approves Teleflex 's (NYSE: TFX ) Arrow-Clark VectorFlow Chronic Hemodialysis Catheter via its 510(k) review process. The catheter has a symmetrical tip design that makes it easier to place and maintain high flows with minimal recirculation. Post your comment!
from April 2013 high] due to disappointing Q2 and lowered guidance for 2013, the mid-cap medical-devices company Teleflex [ TFX ; yield 1.7%; forward P/E 15] is attractive on valuation. 2013 is shaping up as the 4 th good year for spinoffs
We are no longer providing equity research on Teleflex TFX . We provide broad coverage of more than 1,700 companies across 91 industry groups, and we adjust our coverage as necessary based on client demand and investor interest.
balance sheet with debt, which gives Teleflex less flexibility to make future acquisitions ..... care, a segment that is not only Teleflex 's most profitable business, but ..... model discounts the dollar value of Teleflex 's future economic profits (including
acquisitions for its medical segment. Teleflex 's relatively low-margin commercial ..... with those of outside shareholders. Teleflex manufactures products ranging from ..... long term.Teleflexhttp://www. teleflex .com/investor/corporateProfile
Industrial conglomerate Teleflex TFX announced the sale of its Power Systems ..... to Fuel Systems Solutions today. Teleflex will receive $14.5 million for ..... the book value of Power Systems. Teleflex will record this difference as a
We're putting Teleflex TFX under review while we examine our assumptions.